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Parkinson’s disease (PD) is a neurodegenerative disorder that markedly affects
voluntary action. While regular dopamine treatment can help restore motor function,
dopamine also influences cognitive portions of the action system. Previous studies have
demonstrated that dopamine medication boosts action-effect associations, which are
crucial for the discovery of new voluntary actions. In the present study, we investigated
whether neural processes involved in the discovery of new actions are altered in PD
participants on regular dopamine treatment, compared to healthy age-matched controls.
We recorded brain electroencephalography (EEG) activity while PD patients and age-
matched controls performed action discovery (AD) and action control tasks. We found
that the novelty P3, a component normally present when there is uncertainty about
the occurrence of the sensory effect, was enhanced in PD patients. However, AD was
maintained in PD patients, and the novelty P3 demonstrated normal learning-related
reductions. Crucially, we found that in PD patients the causal association between an
action and its resulting sensory outcome did not modulate the amplitude of the feedback
correct-related positivity (fCRP), an EEG component sensitive to the association between
an action and its resulting effect. Collectively, these preliminary results suggest that
the formation of long-term action-outcome representations may be maintained in PD
patients on regular dopamine treatment, but the initial experience of action-effect
association may be affected.
Keywords: Parkinson’s disease, action discovery, ERPs, agency
INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative disorder caused by the progressive loss of
dopamine neurons (Agid and Blin, 1987), which affects both motor and non-motor function.
While dopamine medication (usually in the form of levodopa: L-dopa, a precursor of brain
dopamine) is commonly used to restore motor function, exogenous elevation of dopamine has
been linked to changes in dopamine-related signaling in the basal ganglia (e.g., Gotham et al.,
1988; Cools et al., 2001, 2010; Frank et al., 2004; O’Reilly and Frank, 2006; Moustafa et al.,
2008). Individuals with PD who are ON dopamine medication are shown to have increased
sensitivity to reward feedback (Frank et al., 2004), exaggerated working memory updating
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(Moustafa et al., 2008), and enhanced action-outcome binding
(Moore et al., 2010).
Crucially, the dopaminergic-system has a significant
modulatory role in learning (Reynolds et al., 2001), and
likely shapes the discovery of novel action-sensory outcome
associations that make up adaptive behavior (Redgrave and
Gurney, 2006; Redgrave et al., 2008, 2011; Franz, 2012). Based
on the temporal dynamics of dopamine activity, it has been
recently proposed that the dopamine-system provides both
fast responses to salient events and slow responses that are only
executed after the information has been highly processed (Joshua
et al., 2009). This allows the dopamine-system to participate
in both the monitoring of salient stimuli and the evaluation
of information for modifying future behavior. These dynamic
signals, however, may be affected in dopamine-medicated
individuals with PD leading to changes in the monitoring and
evaluation of behaviorally relevant stimuli.
Detecting the occurrence of salient external events and
evaluating the cause of salient events is essential for learning
and maintaining adaptive behavior (Redgrave and Gurney, 2006;
Redgrave et al., 2008). Using event-related potentials (ERPs),
derived from electroencephalography (EEG), we have previously
shown that the discovery of novel action-outcome associations
is dependent on an interaction between salience monitoring
and evaluation of novel sensory information with regard to
the preceding movement (Bednark et al., 2013). Two key ERPs
were demonstrated to play a role: the feedback correct-related
positivity (fCRP), and the novelty P3.
The fCRP, along with other reward-related potentials, is
commonly associated with themonitoring of salient, positive and
reward-related outcomes (Holroyd et al., 2008, 2011). Related
to action, previous work has shown that the fCRP response to
salient outcomes is enhanced when participants have a sense
of control over the salient outcome (Li et al., 2011; Bednark
et al., 2013; Bednark and Franz, 2014). Conversely, the novelty P3
is thought to reflect the engagement of evaluative processes
necessary for learning when a novel stimulus is encountered
(Friedman et al., 2001; Jongsma et al., 2006; Sailer et al., 2010).
We have shown that the learning of novel actions directly
modulates the novelty P3, with the amplitude of the novelty P3 in
response to the behaviorally relevant outcome decreasing as task
performance improves and participants acquired a novel action
(Bednark et al., 2013). Importantly, both of these brain potentials
have been associated with dopamine activity (de Bruijn et al.,
2005; Poceta et al., 2006; Polich and Criado, 2006; Potts et al.,
2006; Holroyd et al., 2008) and may separately reflect dopamine-
related salience monitoring and evaluative processes.
In the present study, we use these brain potentials to
investigate whether the dynamics of the dopamine-system,
associated with the discovery of new actions, are altered in
individuals with PD while ON regular dopamine treatment
(forms of L-dopa), compared to healthy age-matched controls.
To test this, medicated individuals with PD and age-matched
controls performed action discovery (AD) and action control
tasks similar to our previous study (Bednark et al., 2013). Given
that dopamine is implicated in mediating both the fCRP and the
novelty P3, we expect that both potentials will be enhanced in PD
patients compared to controls. However, dopamine-medication
boosting of action-effect associations is hypothesized to alter AD.
MATERIALS AND METHODS
Participants
Eight patients with mild to moderate PD were recruited from
the participant pool of the Action, Brain, and Cognition
Laboratory at Otago, a program that works in close
association with the Otago Parkinson’s Society, Dunedin,
New Zealand (see Table 1 for patient details). The inclusion
criteria were: no known dementia (Mini-Mental State Exam
score ≥27), no current depressive symptoms (Geriatric
TABLE 1 | Demographic, pathology, and drug details in Parkinson’s disease (PD) patients and controls.
Patient ID Gender Age UPDRS (motor) Duration of disease GDS MMSE Medication (mg/day)
1 F 49 17 8 1 30 Levodopa (150), benserazide (37.5),
orphenadrine (50)
2 F 77 5 8 0 26 Levodopa (100), benserazide (28.5),
lisuride (0.2), orphenadrine (50)
3 M 72 8 7 2 30 Levodopa (400), carbidopa (100),
benztropine (1)
4 F 62 44 12 1 29 Levodopa (96), benserazide (24),
ropinirole (8)
5 F 59 18 3 2 29 Levodopa (700), carbidopa (175)
6 F 66 49 9 2 28 Levodopa (400), carbidopa (100)
7 F 68 11 2 2 28 Levodopa (800), carbidopa (200),
ropinirole (4.5)
8 M 69 42 9 4 29 Levodopa (1950), carbidopa (487.5),
entacapone (600)
PD Mean (SD) 2M and 7F 65.25 (8.65) 24.25 (17.81) 7.25 (3.28) 1.75 (1.17) 28.63 (1.30)
AMC Mean (SD) 2M and 7F 64.88 (9.25) - - 1.13 (1.46) 29.63 (0.52)
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FIGURE 1 | Diagram of the experimental tasks. For action discovery (AD) task (A), the initial-cue (IC) task (B), and the continuous-cue (cc) task (C) the sensory
effect (green circle) was presented when participants moved the cursor into the “hot spot”. In the action control tasks (B,C), the pre-task screen provided information
about the location of the “hot spot”. After each presentation of the sensory effect the cursor was reset to a new location. Participants attempted to elicit the sensory
effect after each cursor reset. Dashed-line circle indicates the location of the “hot spot” when it was not visible to the participant and the green circle represents the
sensory effect. In the stimulus-response (SR) task (D) participants made voluntary movements, however, the presentation of the sensory effect was unrelated to their
movements. Presentation of the sensory effect was computer-controlled. Participants responded to the green circle by moving the cursor to the fixation cross and
then continued to make voluntary movements around the screen.
Depression Scale score ≤5), and currently on dopamine
medication.
Eight age- and sex-matched healthy controls were recruited
from a University of Otago database of older adults participants
(Table 1). Inclusion criteria were: no known neurological or
psychiatric illnesses, no known dementia (MMSE score ≥27),
and no current depressive symptoms (GDS score ≤5). The
Lower South Otago Regional Ethics Committee approved all
procedures. All participants volunteered and gave their fully
informed written consent.
Experimental Procedure
Prior to the experimental session, patients and controls
were interviewed. During the interview, current medical
history was obtained, including current PD treatment
medication for patients. Neuropsychological tests were
also administered to screen for dementia and depression.
The motor portion of the UPDRS was administered to
patients.
Tasks
For the AD and two action control tasks, participants were
informed that their goal was to cause a green circle to appear in
the center of the screen by moving the cursor on the screen using
a tracking-ball mouse. They were further instructed to look at the
fixation cross throughout the trials.
For the AD task, participants were not given any specific
instructions about how to elicit the green circle, but they were
told that they would learn how to do so over the course of the
task. A diagram of the AD task can be seen in Figure 1A. The
green circle was elicited by the participants’ movements when
the cursor was moved into a specific location or ‘‘hot spot’’.
The location of the ‘‘hot spot’’ remained the same within a
block of 30 trials or 30 presentations of the green circle, but
each block had a different location for the ‘‘hot spot’’. The
cursor was re-located to a new random starting point after each
presentation of the green circle. This was done so that the final
position, and not the initial position of the movement, was the
critical determinant of eliciting the presentation of the green
circle. Participants had to then re-locate this location for each
trial.
During the AD task, the monitoring and evaluation of the
sensory effect was required to identify the movement(s) eliciting
the sensory outcome. Over the course of the AD task, participants
learned a set of efficient rules that guided action selection or
a movement heuristic. This AD task was compared to two
non-learning goal-directed motor tasks to investigate how the
monitoring and evaluation of sensory outcomes may differ
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during AD. As a final control task, we used a stimulus-response
(SR) task to investigate the monitoring of behaviorally relevant
sensory effects that were unrelated to the preceding voluntary
movement.
In the initial cue (IC) action-control task, location of the ‘‘hot
spot’’ for eliciting the green circle was cued at the start of the
block with a gray outline of a circle (Figure 1B). Participants were
instructed that moving the cursor into this screen location would
elicit the green circle, but that the gray outline circle would not be
present when they performed the task. The cue was then removed
and participants began this IC task. This IC provided participants
with sensory information for performing the necessary actions
for achieving the task goal prior to the start of the task, thereby
serving as a control for learning novel actions during the AD task.
The continuous cue (CC) action-control task served as a
control for any memory processes or uncertainty (particularly
with regards to the novelty P3) associated with remembering
the cued location in the IC task or the learnt location
in the AD task. At the start of the CC task, participants
were instructed that moving the cursor into the location
defined by a gray outline of a circle on the screen would
elicit the green circle (Figure 1C). For action-outcome task
(Figures 1A–C) the cursor was re-positioned to a different
location on the screen following each presentation of the green
circle.
The final control task was a SR task (Figure 1D). For the
SR task, participants were informed that their movements did
not elicit the sensory effect. Rather, they were instructed to
move the cursor around the screen (so participants were still
making voluntary movements) and respond to the presentation
of the green circle by moving the cursor to the fixation cross
(so the green circle was still salient) and then resume moving
the cursor around the screen. To control for the reduction
in the inter-stimulus interval, which is known to affect P3
amplitude (e.g., Gonsalvez et al., 2007) that is observed with
learning in the AD task, we controlled the timing of green circle
presentation. The timing of the green circle in each block of
the SR task was computer-controlled to have the same inter-
stimulus interval as the corresponding block of the movement-
learning task performed by the same participant (thereby using
yoked timing conditions). As a result, any variation or decrease
in the timing interval of the sensory effects in the movement-
learning task would be directly controlled for by the SR
task.
The behavioral tasks that were administered during the
experimental session were previously conducted in normal
undergraduate participants (Bednark et al., 2013). The theoretical
importance of our AD task has also been highlighted elsewhere
(Stafford et al., 2012). There are, however, a few key differences
between the tasks used in the present study and those
used in our previous ERP study (Bednark et al., 2013). To
reduce the difficulty of the tasks, we increased the size of
the ‘‘hot spot’’ (4.04◦ visual angles) and other visual stimuli
(i.e., fixation cross: 0.8◦; cursor: 0.8◦; green sensory effect:
4.04◦). Additionally, while the three different control tasks
were previously conducted in two separate experiments, the
same group of participants performed all control tasks in the
present study. The order of the tasks was as follows: ABC-
ABC-ABC-DDD or ACB-ACB-ACB-DDD. A total of 12 blocks
was conducted, with a block defined by 30 presentations of the
green circle. The tasks were performed on a 54 cm display with
a black background. MatLab software (MathWorks, Inc.) was
used for all stimulus presentation and collection of behavioral
responses.
Behavioral Analysis
For the AD task and the two action control tasks, the
time it took the participants to elicit each green circle was
recorded. These times were used to determine hit rate, or
the number of green circles presented per 2 s interval.
The hit rate was used as a behavioral measure of goal-
directed motor performance and was calculated for the first
half of green circle occurrences (1–15; F15) and second
half of green circle occurrences (16–30; L15) of each block
in order to investigate changes in performance within a
block.
For the SR task, the time it took the participants to respond to
each green circle by moving to the fixation cross, and the number
of responses made were recorded. The mean response time and
the mean number of responses were computed for the first half
of green circle occurrences (1–15; F15) and second half of green
circle occurrences (16–30; L15) of each block.
EEG Data Acquisition and Analysis
EEG and electrooculography (EOG) data were collected
continuously using a 32-channel Ag-Ag/Cl sintered Quickcap
and a Neuroscan Synamps amplifier, interfaced with a Dell Intel
computer running Scan 4.3 software. Data were sampled at 1000
Hz with a band pass of 0.5–200 Hz, and the gain was ×500.
The 28 scalp electrode sites were referenced to linked mastoid
electrodes, with AFz as the ground. Horizontal EOG data were
recorded from two electrodes placed on the outer canthi of
the two eyes. Vertical EOG data were recorded from linked
electrodes on the infraorbital and supraorbital ridges of the left
eye. Impedances were maintained below 5 k.
EEG data analysis was conducted offline using purpose-
writtenMatLab scripts. Continuous EEG data were epoched with
respect sensory event onset (200 ms prior and 1000 ms after) in
the behavioral task, and baseline corrected relative to the 200 ms
period prior to sensory event onset. Prior to averaging, epochs
containing ocular artifacts were corrected (Gratton et al., 1983).
To remove movement artifact associated with PD, EEG data
were then wavelet decomposed to level 9 using a ‘‘Daubechies
6’’ discrete wavelet transformation, and reconstructed with 1–25
Hz-frequency range. Based on visual inspection of the averaged
waveforms, the mean amplitude of the fCRP for both PD
and AMC groups was measured at the Cz electrode site and
averaged across the time window 210–290 ms. For the novelty P3
(measured at CZ) we created a mean amplitude measure for the
peak amplitude (averaged 25 ms before and after the peak) found
within the 300–450 ms time window. This was done to reduce
variation in the latency of the novelty P3 component observed in
the patient and control group when the waveforms were visually
Frontiers in Human Neuroscience | www.frontiersin.org 4 August 2016 | Volume 10 | Article 427
Bednark et al. ERPs of Movement-Outcome Learning in PD
inspected. For plotting purposes, EEG data were smoothed using
a one-dimensional digital filter with a 25 ms time window.
Statistical Analysis
The hit rate behavioral measure was entered into a mixed
analysis of variance (ANOVA) with the within-subjects factors
of Task (AD, CC, IC), Block-Half (F15, L15) and Block
(Block 1, Block 2, Block 3), and between-subject factor
of Group (patients, controls). Similar mixed ANOVAs were
conducted for fCRP and novelty P3 amplitude, but the SR
task added to the Task factor. To tease apart specific effects
of interactions, additional repeated-measures ANOVAs and
planned comparisons were used where appropriate to test our
hypotheses. Effects were considered significant if p < 0.05.
Greenhouse–Geisser corrections were also applied to p-values
where appropriate. Effect sizes are shown using partial eta
squared (η2). For the assessment of behavioral performance
during the SR task, the mean time to response to the stimulus
and the mean number of responses to the stimulus were entered
into paired-sample t-tests that compared the PD and a control
group. All statistical tests were conducted using SPSS (version
18.0) software.
RESULTS
Behavioral Results
For both PD and controls, the hit rate in each task increased
across blocks (Block, F(2,28) = 18.78, p< 0.001, partial η2 = 0.57)
and within blocks (Block-Half, F(1,14) = 37.44, p < 0.001,
partial η2 = 0.73). There was a significant main effect of Task
(F(2,28) = 72.48, p < 0.001, partial η2 = 0.84) demonstrating
that the hit rate during the AD task (M = 0.85, SE = 0.08) was
significantly smaller than in the CC task (M = 1.64, SE = 0.09,
p < 0.001) and the IC task (M = 1.68, SE = 0.09, p < 0.001).
A significant Task × Block-Half interaction (F(2,28) = 33.59,
p < 0.001, partial η2 = 0.71) suggested that performance was
improving at a greater rate during the AD task. Verifying
learning-related improvement, post hoc paired-samples t-tests
showed that the change in hit ratewithin a block was significantly
larger for the AD task (M = 0.40, SE = 0.05) compared to
the CC task (M = 0.10, SE = 0.04, t(47) = 4.69, p < 0.001)
and the IC task (M = −0.06, SE = 0.05, t(47) = 8.54,
p< 0.001).
Regarding the difference in behavioral performance
between groups, we did not find any significant difference
between groups in hit rate (Figure 2A). Though the hit
rate of the PD group was generally less than that of the
control group. There were also no significant differences
between groups in mean response time (F(1,14) = 1.69,
p = 0.21, partial η2 = 0.11) and number of responses
(F(1,14) = 0.19, p = 0.67, partial η2 = 0.01) during the SR
task (Figures 2B,C).
fCRP Results
The average ERP waveforms for each task and group are
presented in Figure 3. We found a significant Task × Group
FIGURE 2 | Behavioral performance for the Parkinson’s disease (PD)
and AMC groups. (A) The hit rate for each block-half (F15, L15) of the AD
task, the CC task, and the IC task, showing a general improvement in
performance across all tasks. (B) Mean response time and (C) mean number
of responses from the SR task for each group. Overall behavioral performance
across the two groups was similar. Error bars indicate standard error.
interaction in the amplitude of the fCRP (F(3,42) = 3.73, p= 0.03,
partial η2 = 0.21). As shown in Figure 4A, subsequent post hoc
analysis revealed that the magnitude of the fCRP during the
SR task was significantly larger in amplitude in the PD group
(M = 6.53 µV, SE = 0.80 µV) compared to the control group
(M = 3.28 µV, SE = 0.80 µV; Group, F(1,14) = 8.40, p = 0.012,
partial η2 = 0.375; Bonferroni corrected α-level = 0.0125).
Initial analysis also suggests that the magnitude of the fCRP
response for both groups demonstrated a reduction across
Block-Half (F(1,14) = 4.84, p = 0.045, partial η2 = 0.26) and
Block (F(2,28) = 5.15, p = 0.013, partial η2 = 0.27). However,
when each group was assessed individually, only the PD group
demonstrated significant reductions in fCRP amplitude across
Block-Half (F(1,14) = 4.84, p = 0.045, partial η2 = 0.26)
and Block (F(2,28) = 5.15, p = 0.013, partial η2 = 0.27).
In the control group, there was a significant main-effect of
Task (F(3,21) = 4.48, p = 0.033, partial η2 = 0.39) with the
difference observed between the AD task (M = 5.14 µV,
SE = 0.60 µV) and the SR task (M = 3.28 µV, SE = 0.60 µV,
p = 0.022; Bonferroni corrected α-level = 0.016), as shown in
Figure 4A.
Novelty P3 Results
As shown in Figure 4B, the magnitude of the novelty P3 response
in the PD group was significantly larger than the novelty P3
response in the control group (Group, F(2,14) = 4.48, p = 0.034,
partial η2 = 0.43). However, while the novelty P3 amplitude
for the PD group was larger than in the control group, the
general trend of novelty P3 response is similar for the two
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FIGURE 3 | Average event-related potential (ERP) waveform at Cz electrode site from the PD group and the AMC group during (A) the AD task, (B) the
CC task, (C) the IC task, and (D) the SR task.
groups (Figure 4C). There was also a significant main-effect
of Task overall, (F(3,42) = 4.48, p = 0.034, partial η2 = 0.43).
Bonferroni pair-wise comparisons revealed that the novelty P3
response during the AD task (M = 11.77 µV, SE = 0.89 µV)
was significantly larger than in the IC task (M = 7.03 µV,
SE = 0.49 µV, p < 0.001) and CC task (M = 7.53 µV, SE = 0.48
µV, p < 0.001). The SR task (M = 10.65 µV, SE = 0.96 µV)
was also significantly different from the IC task (p = 0.003)
and the CC task (p = 0.017). However, no difference between
the AD task and the SR task was observed. The novelty P3
response also demonstrated a significant reduction across Block-
Half (F(1,14) = 4.48, p = 0.034, partial η2 = 0.43), and Block
(F(2,28) = 4.48, p= 0.034, partial η2 = 0.43).
This pattern of significant main effects was observed in both
PD and control groups, as confirmed by separate analyses on
each group. Accordingly, in the PD group, there were significant
main effects of Task (F(3,21) = 14.13, p= 0.001, partial η2 = 0.67),
Block-Half (F(1,7) = 27.27, p = 0.001, partial η2 = 0.80), and
Block (F(2,12) = 6.04, p = 0.021, partial η2 = 0.46). The pattern
was similar for the control group: Task (F(3,21) = 7.36, p= 0.006,
partial η2 = 0.51), Block-Half (F(1,7) = 13.59, p = 0.008,
partial η2 = 0.66), and Block (F(2,14) = 6.30, p = 0.027, partial
η2 = 0.47).
DISCUSSION
The present study investigated the neural processes mediating
the discovery of novel actions in PD patients currently receiving
dopamine treatment. We found no significant behavioral
differences in AD between PD patients and age-matched
controls. However, ERP analysis suggests that there may be
significant alterations to the neural processes involved in
the formation of action-outcome associations in PD patients
compared to controls.
Novelty P3
As hypothesized, the amplitude of the novelty P3 was
larger in people with PD compared to age-matched controls.
This effect is complementary to previous work that has
demonstrated a reduction in novelty P3 amplitude in PD
patients OFF dopamine medication (Poceta et al., 2006). Indeed,
evidence from multiple studies suggests that dopamine is a
crucial neuromodulator of the novelty P3 response (Polich
and Criado, 2006; Polich, 2007). This would suggest that
dopamine levels modulate the response to salient unexpected
sensory events, which is in keeping with the dopamine error-
signaling hypothesis (Schultz, 1997, 1998). Additionally, this
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FIGURE 4 | ERP results for PD and AMC groups. (A) Feedback correct-related positivity (fCRP) amplitude in the PD and AMC groups for the AD task, CC task,
IC task, and SR task. There was a significant difference in fCRP amplitude between the PD group and the AMC group in SR. For the AMC group, fCRP amplitude in
SR was significantly reduced compared to AD. (B) There was an overall significant enhancement in novelty P3 amplitude in the PD group compared to the AMC
group. (C) However, the general trend of the novelty P3 was similar across the different tasks for both groups. Error bars indicate standard error. ∗p < 0.05.
enhancement of the novelty P3 provides further evidence
for the proposed over-abundance of dopamine in relatively
preserved portions of the basal ganglia (Gotham et al., 1988;
Swainson et al., 2000; Cools et al., 2001; Shohamy et al.,
2006). In contrast to previous EEG studies, our results suggest
that the mechanisms governing the reduction of the novelty
P3 are unaffected or restored in medicated individuals with
PD.
In both PD patients and age-matched controls, the novelty
P3 demonstrated learning-related reductions within and across
blocks of the AD task. Previously, we hypothesized that the
novelty P3 reflects the engagement of attentional mechanisms
necessary for identifying the movements responsible for the
unexpected sensory event (Franz, 2012; Bednark et al., 2013).
As the responsible movements are identified and a heuristic
is formed to guide future action selection, the need to engage
attentional mechanisms is reduced. In the present study,
we found that the novelty P3 response in PD patients still
demonstrated learning-related reductions. This would suggest
that neural processes mediating action-outcome anticipation
might be unaffected by changes to the magnitude of the
dopamine response or that dopamine medication restores
function to this system.
According to previous AD proposals of the dopamine error
signal, the formation of long-term associations between actions
and outcomes are likely established in structures outside the
basal ganglia (Redgrave and Gurney, 2006; Redgrave et al.,
2008). One such brain structure is anterior cingulate cortex
(ACC). Recent evidence indicates that the ACC is responsible
for governing the value of actions based on their previous
reinforcement history (Walton et al., 2004; Rushworth et al.,
2007; Holroyd and Coles, 2008). The ACC is the proposed
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source generator of the novelty P3 (Polich, 2007), and is thought
to receive the dopamine error signal from the basal ganglia
(Holroyd and Coles, 2002, 2008). While original proposals
of this ACC-dopamine error signaling (Holroyd and Coles,
2002) have focused on prediction errors that are derived from
subcortical indications of stimulus novelty (for a review see
Redgrave et al., 2008, 2011), recent evidence from animal
studies suggests that the dopamine error signal (with a longer
latency) can be elicited from cortical indications of stimulus
novelty (Bromberg-Martin et al., 2010; Nomoto et al., 2010).
Along these lines, there is evidence that the ACC can directly
modulate dopamine release (Gariano and Groves, 1988). Indeed,
it has been proposed that different time scales of the dopamine
response may control different aspects of motor behavior
(Joshua et al., 2009). Thus, the ACC may govern the learning-
related reductions in the novelty P3 response through its
modulation of dopamine signaling. This possible top-down
mechanism appears to remain moderately intact or is restored
to normal function in PD patients on regular dopamine
treatment.
fCRP
In the motor tasks in which participants’ actions were
responsible for the occurrence of the sensory event, there
was no significant difference between PD patients and age-
matched controls. Crucially, when the participants’ actions
were unrelated to the occurrence of the sensory event, we
observed an enhancement in the fCRP response in PD patients
compared to age-matched controls. As highlighted in the
Introduction, previous studies have demonstrated that the fCRP
response is enhanced by the perceived responsibility over Li
et al. (2011) and coupling of an intentional action with a
sensory event (Bednark et al., 2013; Bednark and Franz, 2014).
Additionally, it has been previously demonstrated that PD
patients on regular dopamine treatment perceive actions and
sensory events as occurring closer in time than when OFF
dopamine treatment (Moore et al., 2010). These converging
lines of evidence would suggest that PD patients had an
exaggerated experience of association between their actions
and the sensory effect during the SR task. This is despite
explicit knowledge that their actions were not responsible for
the sensory effect. Presumably this could be because dopamine
treatment used to restore dopamine levels in PD patients
may actually reduce the dynamic range of the dopamine
response (Frank, 2005). This, in turn, may reduce the fCRP
differentiation between action-related and action-unrelated
sensory effects.
In contrast to the novelty P3, the pattern of fCRP response
across and within tasks in PD patients varied significantly from
the fCRP pattern observed in age-matched controls. This would
suggest that the processes involved in the fCRP response might
be altered in PD patients. A recent source localization study
that used principal component analysis to remove the influence
of other ERPs demonstrated that the basal ganglia is the likely
source generator of the reward-related fCRP response (Foti
et al., 2011). Applied to our findings, this would suggest that
alterations to the fCRP response in PD patients may occur at the
level of the basal ganglia. Thus, in PD patients ON medication,
it appears that over-abundant dopamine levels in relatively
preserved portions of the basal ganglia causes the behavioral
relevance of the sensory effect to be maintained across all tasks.
An alternative possibility is that the enhanced fCRP may be
related to increased task motivation. Others have suggested that
task motivation can modulate brain activity in the time-range of
the fCRP (Hajcak et al., 2005; Boksem et al., 2006; Sailer et al.,
2010). However, it is unlikely that task motivation in the PD
patients was only enhanced during the SR task. Nevertheless,
reduced task motivation may explain the observed reduction in
fCRP amplitude within and across blocks in the PD patients.
Limitations and Future Directions
The low number of individuals with PD available for this study
and the lack of an OFF-medication state in the PD group limits
the extent to which these results can be generalized; the present
findings must be viewed as preliminary. However, it is important
to note that despite the small sample size and heterogeneity of
the PD observed in these patients, we were still able to find
significant differences in our ERP measures. Thus, this study
provides initial evidence for the use of ERPs in exploring PD.
Future studies with access to larger patient populations and
ON/OFF design should be conducted to determine the extent to
which these ERPs are influenced by dopaminemedication during
agent-based action learning. However, performing a study with
ON/OFF design may prove to be difficult given the learning
nature of this task. Differences between the ON and OFF state
may not be detected because carry-over effects (e.g., learning the
task) affect performance in the task from one state to the next.
Conducting this experiment with de novo PD patients who still
have a normal level of motor control could potentially reveal
if action learning mechanisms are affected before gross motor
control effects are visible.
Conclusion
This is an initial study investigating whether the ability to
identify new actions might be affected in dopamine medicated
PD participants. AD is maintained in PD patients on regular
dopamine treatment despite a potential over-abundance of
dopamine in relatively preserved portions of the basal ganglia.
This highlights the importance of structures outside the
basal ganglia for the formation of long-term action-outcome
representations. However, the initial experience of action-
outcome association appears to be affected by increased
dopamine levels in the basal ganglia.
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